Sign in

Private company

Merz Therapeutics

Logo: Lena Falkenberg, CC BY-SA 4.0, via Wikimedia Commons3

Merz Therapeutics is a German company based in Frankfurt.1

Die Merz Pharma GmbH & Co. KGaA, kurz auch Merz, ist ein internationales Unternehmen mit Hauptsitz in Frankfurt am Main. Das Unternehmen entwickelt und produziert unter anderem Produkte und Medizintechnikgeräte für die ästhetische Medizin, Arzneimittel für Patienten, die an neurologischen Bewegungsstörungen leiden, sowie weitere verschreibungspflichtige Medikamente.2 From the German Wikipedia, CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

See how the biggest companies compare on our leaderboards

Calendar

Drug trials and FDA: coming up

  1. Mar 2027Phase 3 trial readout expected Phase 3 trial of Xeomin in Episodic Migraine: primary completion expected Mar 2027 (ClinicalTrials.gov NCT07018700).4
  2. Mar 2027Phase 3 trial readout expected Phase 3 trial of Xeomin in Chronic Migraine: primary completion expected Mar 2027 (ClinicalTrials.gov NCT07018713).5

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5